RYTM Q3 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+316.7% YoY

Gross Profit

$4M88.4% margin

Operating Income

-$39M-916.6% margin

Net Income

-$41M-953.8% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-52.7%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$390M

Total Liabilities

$108M

Stockholders' Equity

$281M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$1M	+316.7%
Gross Profit	$4M	$806,000	+369.9%
Operating Income	-$39M	-$44M	+11.2%
Net Income	-$41M	-$35M	-16.4%

Revenue Segments

Product revenue

$4M100%